RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
28 août 2023 06h35 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the...
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
28 juil. 2023 13h24 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring...
First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal
28 juil. 2023 12h26 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic...
Analysis of Global Artificial Eye Markets, 2023-2030: Unveiling the Major Opportunities by Region
27 juil. 2023 05h03 HE
|
Research and Markets
Dublin, July 27, 2023 (GLOBE NEWSWIRE) -- The "Global Artificial Eye Markets, 2023-2030" report has been added to ResearchAndMarkets.com's offering. Global Artificial Eye Market to Reach USD 1.14...
Despite Impressive Early Uptake of Apellis’ Syfovre in Geographic Atrophy, US Ophthalmologists Struggle to Articulate the Complement Inhibitor’s Value Proposition to Potential Patients
28 juin 2023 13h32 HE
|
Spherix Global Insights
Exton, Pennsylvania, June 28, 2023 (GLOBE NEWSWIRE) -- With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy (GA), patients...
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
26 juin 2023 06h15 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board...
Nearly One Year Post-Launch Biogen & Coherus Biosciences’ Ranibizumab Biosimilars Have Yet to Make a Splash in Their Respective Retina Markets
23 juin 2023 11h41 HE
|
Spherix Global Insights
Exton, Pennsylvania, June 23, 2023 (GLOBE NEWSWIRE) -- Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars...
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
07 juin 2023 05h35 HE
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Mr. Watson’s...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
05 juin 2023 06h00 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of...
Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation
24 mai 2023 10h12 HE
|
Curative Biotechnology, Inc.
Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or...